Albuterol — Membership Pricing

Related medications

Other medications associated with the same conditions in this catalog.

Also listed for Asthma / Acute Bronchospasm

• Budesonide
• Fluticasone
• Ipratropium
• Montelukast
• Salmeterol
• Tiotropium

Other medications in Respiratory

• Cromolyn Sodium Inhaler
• Theophylline ER
• Treprostinil Oral
• Zafirlukast
• Zileuton

What Albuterol is approved for (FDA label)

Albuterol Sulfate HFA is a beta 2 -adrenergic agonist indicated for: Treatment or prevention of bronchospasm in adult and pediatric patients aged 4 years and older with reversible obstructive airway disease. ( 1.1 ) Prevention of exercise-induced bronchospasm in adult and pediatric patients aged 4 years and older. ( 1.2 ) 1.1 Bronchospasm Albuterol Sulfate HFA Inhalation Aerosol is indicated for the treatment or prevention of bronchospasm in adult and pediatric patients aged 4 years and older with reversible obstructive airway disease. 1.2 Exercise-Induced Bronchospasm Albuterol Sulfate HFA is indicated for the prevention of exercise-induced bronchospasm in adult and pediatric patients aged 4 years and older.

Source: Read the full FDA label on DailyMed. Label effective date: December 31, 2024.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Albuterol (FDA label)

Inhalation aerosol: 108 mcg of albuterol sulfate (90 mcg of albuterol base) from the mouthpiece per actuation. Blue plastic inhaler with a blue cap containing a pressurized metered-dose aerosol canister containing 200 metered inhalations and fitted with a counter. Inhalation aerosol: 108 mcg albuterol sulfate (90 mcg albuterol base) per actuation. ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: 04c8a345-0a0d-5a01-e063-6294a90a40d2. SPL document ID: 2a996b2b-b5da-65e7-e063-6394a90adeed. Label effective date: December 31, 2024. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Albuterol (FDA label)

The following clinically significant adverse reactions are described elsewhere in the labeling: Paradoxical bronchospasm [see Warnings and Precautions ( 5.1 )] Cardiovascular effects [see Warnings and Precautions ( 5.4 )] Hypersensitivity reactions, including anaphylaxis [see Warnings and Precautions ( 5.6 )] Hypokalemia [see Warnings and Precautions ( 5.8 )] Most common adverse reactions (incidence ≥3%) are throat irritation, viral respiratory infections, upper respiratory inflammation, cough, and musculoskeletal pain. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Prasco Laboratories at 1-866-525-0688 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: 04c8a345-0a0d-5a01-e063-6294a90a40d2. SPL document ID: 2a996b2b-b5da-65e7-e063-6394a90adeed. Label effective date: December 31, 2024. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Albuterol (FDA label)

Albuterol Sulfate HFA is contraindicated in patients with a history of hypersensitivity to any of the ingredients [see Warnings and Precautions ( 5.6 ), Description ( 11 )] . Hypersensitivity to any ingredient. ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: 04c8a345-0a0d-5a01-e063-6294a90a40d2. SPL document ID: 2a996b2b-b5da-65e7-e063-6394a90adeed. Label effective date: December 31, 2024. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Albuterol (FDA label)

Other short-acting sympathomimetic aerosol bronchodilators should not be used concomitantly with albuterol. If additional adrenergic drugs are to be administered by any route, they should be used with caution to avoid deleterious cardiovascular effects. Beta-blockers: Use with caution. May block bronchodilatory effects of beta-agonists and produce severe bronchospasm. ( 7.1 ) Diuretics: Use with caution. Electrocardiographic changes and/or hypokalemia associated with non–potassium-sparing diuretics may worsen with concomitant beta-agonists. ( 7.2 ) Digoxin: May decrease serum digoxin levels. Consider monitoring digoxin levels. ( 7.3 ) Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. May potentiate effect of albuterol on vascular system. ( 7.4 ) 7.1 Beta-Adrenergic Receptor Blocking Agents Beta-blockers not only block the pulmonary effect of beta-agonists, such as albuterol sulfate HFA, but may also produce severe bronchospasm in patients with asthma. Therefore, patients with asthma should not normally be treated with beta-blockers.

Source: FDA prescribing information (DailyMed). Set ID: 04c8a345-0a0d-5a01-e063-6294a90a40d2. SPL document ID: 2a996b2b-b5da-65e7-e063-6394a90adeed. Label effective date: December 31, 2024. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.